About Flying L Partners
Flying L Partners is a venture capital firm founded in 2016. It is primarily based out of Newport Beach, United States. As of Apr 2022, Flying L Partners has invested in 11 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and Nonprofits. Most recently it participated in the $***** Series C round of Aurion Biotech Overall, Flying L Partners portfolio has seen 1 IPO and 5 acquisitions including key companies like Tarsus, RxSight and Aurion Biotech. A lot of funds co-invest with Flying L Partners, with names like Visionary Ventures sharing a substantial percentage of its portfolio. Flying L Partners has team of 4 people including 3 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 3 more
Portfolio IPOs
Portfolio Acquisitions
Flying L Partners' List of Top Investments
Flying L Partners has a portfolio of 11 companies. Their most notable investments are in Surface Pharma and AcuFocus.Their portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, Nonprofits, across Series B, Series A and 3 more. Here is the list of top investments by Flying L Partners:
1. Tarsus
Tarsus is developing a drug to treat blepharitis. The lead compound is a topical ophthalmic drug called TP-03 developed for the treatment of Demodex blepharitis will undergo Phase 2b/3 trials. The company's product pipeline also includes the development of drugs for other eye problems.
Key facts about Tarsus
- Founded Year: 2017
- Location: Irvine (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $60M
- Employee Count: 436 as on Aug 31, 2026
- Investors: RTW Investments, Vivo Capital and 5 Others
- Latest Funding Round: Series B, Jan 08, 2020, $*****
- Highlight: Acquired
2. RxSight
RxSight (formerly known as Calhoun Vision) has developed an adjustable intraocular lens technology. It uses biocompatible materials called macromers which are sensitive to ultraviolet light of a certain wavelength. When irradiated by such light, the macromers undergo photopolymerization, leading to a predictable change in the shape of the lens surface.
Key facts about RxSight
- Founded Year: 1997
- Location: Aliso Viejo (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $194M
- Employee Count: 406 as on Aug 31, 2026
- Investors: HTIF, Foresite Capital and 10 Others
- Latest Funding Round: Conventional Debt, Dec 02, 2020, $*****
- Highlight: Public
Developer of regenerative cell therapies for ocular diseases. The lead candidate Vyznova is for the treatment of corneal endothelial disease. The company collects healthy cells from a donor cornea which is propagated and used for the treatment.
Key facts about Aurion Biotech
- Founded Year: 2021
- Location: Seattle (United States)
- Stage: Acquired
- Total Funding till date: $120M
- Employee Count: 117 as on Aug 31, 2026
- Investors: Deerfield, Petrichor and 5 Others
- Latest Funding Round: Series C, Apr 12, 2022, $*****
- Highlight: Acquired
4. Neurolens
Provider of prescription lenses and solution for problems related to Digital Vision Syndrome. The company has a patented Contoured Prism technology and is the first and only prescription lenses to provide comfort for the majority of adults who complain of headaches, neck/shoulder pain, and eyestrain when using digital devices, reading, or doing detail work, the daily symptoms of Digital Vision Syndrome, DVS. With this technology, the company corrects eye misalignment naturally and provides comfortable vision.
Key facts about Neurolens
- Founded Year: 2008
- Location: Coppell (United States)
- Stage: Series E
- Total Funding till date: $126M
- Employee Count: 132 as on May 31, 2026
- Investors: Marshall Wace, Trinity Capital and 5 Others
- Latest Funding Round: Venture Debt, Dec 06, 2023, $*****
- Highlight: Editors' Pick
5. CorneaGen
CorneaGen focuses on developing therapeutic devices for a corneal transplant. The corneal products developed are Ampho B, Pre-Loaded Cannula, Cannula, Donor Punch, EndoSerter, and Recipient Trephine.
Key facts about CorneaGen
- Founded Year: 2017
- Location: Seattle (United States)
- Stage: Series B
- Total Funding till date: $44M
- Employee Count: 179 as on Aug 31, 2026
- Investors: CYwP Funds, Petrichor and 2 Others
- Latest Funding Round: Conventional Debt, Oct 07, 2019, $*****
- Highlight: Editors' Pick
Flying L Partners' Year-on-Year Investment Trends
Flying L Partners has invested in 11 companies over the last 10 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Aurion Biotech.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 0 | 0 |
2023 | 0 | 0 | 0 |
2022 | 1 | 0 | 1 |
2021 | 0 | 0 | 0 |
2020 | 2 | 0 | 2 |
2019 | 3 | 0 | 3 |
2018 | 2 | 0 | 2 |
2017 | 1 | 0 | 1 |
Flying L Partners' Investments by Stage
Flying L Partners has made 4 investments in Series B stage with an average round size of $53.1M, 2 investments in Series A stage with an average round size of $12.5M, 2 investments in Series H stage with an average round size of $25M, 1 investment in Series C stage with an average round size of $120M and 1 investment in Series D stage.Stage of entry | No. of Investments |
|---|---|
Series B | 4 |
Series A | 2 |
Series H | 2 |
Series C | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Flying L Partners' Investments by Sector
Flying L Partners has a diverse portfolio, with companies operating in the Life Sciences and Nonprofits. Notably, it has invested in 9 Tech companies, 8 Enterprise (B2B) companies, 4 Tech hardware companies and at least 2 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
Nonprofits | 1 |
Note: We have considered here, only first round of investments
Flying L Partners' Investments by Geography
Flying L Partners has made most investments in United States (10).Flying L Partners' recent investments
Flying L Partners has not made any investment in 2026 so far.Here are the most recent investments by Flying L Partners:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 12, 2022 | United States | Series C | 4813 | [+5] | |
Aug 19, 2020 | United States | Series B | 4099 | [+2] | |
Jan 08, 2020 | United States | Series B | 7508 | [+4] | |
Aug 2019 | United States | Series D | 2672 | - | |
Feb 26, 2019 | United States | Series B | 3172 | [+3] |
IPOs and Publicly Listed companies in Flying L Partners' Portfolio
1 of Flying L Partners' portfolio company became public - RxSight. It got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2021 at marketcap of $424MHere are Flying L Partners' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 30, 2021 | Mar 2017 | Series H | 1323 |
Acquired companies in Flying L Partners' Portfolio
5 companies from Flying L Partners' portfolio have been acquired. The most recent acquisition was Aurion Biotech in Mar 2025 by Alcon for $*****.Here are Flying L Partners' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 26, 2025 | Apr 12, 2022 | Series C | 1759 | |
Jan 17, 2023 | Sep 2018 | Series H | 7565 | |
Nov 07, 2022 | Feb 26, 2019 | Series B | 7918 | |
Aug 10, 2022 | Oct 18, 2016 | Series A | 8158 | |
Jul 07, 2022 | Jan 08, 2020 | Series B | 7257 |
Team profile of Flying L Partners
Flying L Partners has a team of 4 members including 3 Partners located in United States. Flying L Partners' team does not sit on the board of any company as of now.Here is a list of all team members in Flying L Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Laguna Hills | - | - | |
Partner | Steamboat Springs | - | - | |
Partner | Minneapolis | - | - |
Co-investors of Flying L Partners
Over the past 10 years, 36 investors have co-invested in Flying L Partners's portfolio companies. This includes only funds.
- Invested before Flying L Partners: Versant Ventures, HIG BioHealth Partners and 15 others have invested in rounds before Flying L Partners. There are 2 companies where Versant Ventures has invested before Flying L Partners and 1 company where HIG BioHealth Partners has invested before Flying L Partners.
- Top Co-investors of Flying L Partners: 13 investors entered a company along with Flying L Partners. These include investors like Visionary Ventures (2 companies).
- Invested after Flying L Partners: A total of 6 investors have invested in Flying L Partners's portfolio after their investments. Top Investors include Oxford Finance (1 company), Trinity Capital (1 company) and MVM (1 company).
Recent News related to Flying L Partners
•
Aurion Biotech Raises $120M in FundingFinSMEs•Apr 16, 2022•Aurion Biotech, Petrichor, Flying L Partners, Falcon-Vision and 5 others
•
TearClear Raises $22 Million to Advance Multiple Clinical Programs in DevelopmentGlobeNewswire•Aug 11, 2020•TearClear, Visionary Ventures, Bluestem Capital, Flying L Partners and 1 other
•
Tarsus Pharmaceuticals Secures $60M in Series B FinancingFinSMEs•Jan 08, 2020•Tarsus, Vivo Capital, Frazier Healthcare Partners, Flying L Partners and 3 others
•
CorneaGen Raises $37 Million to Advance Development of Cornea Cell TherapyEyewire•Oct 07, 2019•CorneaGen, Flying L Partners, Falcon-Vision, Petrichor and 1 other
•
•
